⌘K
t
Solvonis Therapeutics plc announced on 26 June 2025 that Singer Capital Markets initiated equity research coverage on the Company. Dr. Karl Keegan, Head of Life Sciences Research at Singers, authored the Initiation Note, titled "Psyching up for success." The research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.
| Date | 26 Jun 2025 |
| Time | 10:21:21 |
| Category | Miscellaneous |
| ID | 5618O |
("Solvonis" or the "Company")
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that Singer Capital Markets ("Singers") has today initiated equity research coverage (the "Initiation Note") on the Company.
The Initiation Note, titled "Psyching up for success", has been authored by Dr. Karl Keegan, Head of Life Sciences Research at Singers.
The research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com
Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656
Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.
The Company's programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions which the Company estimates affect over 60 million people across the UK, US, and EU4. Its lead asset, SVN‑001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN‑002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme, SVN‑SDN‑014, leveraging novel serotonin, dopamine, and noradrenalin modulators designed to enhance pro-social behaviour and long-term outcomes.
In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders.
With a capital-efficient model, focused pipeline strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.